GlassScriptPhysician profile
Sorkko Thirunavukkarasu
NPI 1912314626
$4,257.99
in general payments reported to CMS, 2019-2025
25 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.81 · 2021: $698 · 2022: $994 · 2023: $831 · 2024: $1,063 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,468.53 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $610.09 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $452.24 | 2021-2024 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $341.69 | 2020-2025 | Veltassa, Korsuva |
| Amgen INC. | $321.45 | 2020-2025 | Tavneos, Krystexxa, Parsabiv |
| Nxstage Medical, INC. | $287.75 | 2021-2025 | Nxstage System One, Pureflow Sl, Nxstage Pureflow Solution |
| Aurinia Pharma U.S., INC. | $285.21 | 2021-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $281.21 | 2023-2024 | |
| Baxter Healthcare | $279.38 | 2023-2024 | Renal - Acute, Renal - Pd |
| Otsuka America Pharmaceutical, INC. | $237.36 | 2020-2025 | Jynarque |
| Novo Nordisk INC | $145.01 | 2023-2024 | Ozempic |
| Outset Medical INC | $140.31 | 2021 | |
| Akebia Therapeutics INC | $138.51 | 2021-2025 | Vafseo |
| Alexion Pharmaceuticals, INC. | $122.52 | 2022-2025 | Ultomiris |
| Ani Pharmaceuticals, INC. | $117.15 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $88.20 | 2022-2025 | Tarpeyo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72.78 | 2024-2025 | |
| Travere Therapeutics, INC. | $68.05 | 2023-2025 | |
| Abbvie INC. | $50.87 | 2022 | |
| Mallinckrodt Hospital Products INC. | $48.78 | 2021-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $34.96 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.04 | 2024 | Jardiance |
| Horizon Therapeutics Plc | $30.64 | 2023 | Krystexxa |
| Kyowa Kirin, INC. | $26.09 | 2023 | |
| Amarin Pharma, INC. | $24.87 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $19.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sorkko Thirunavukkarasu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.